Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 4/20 | 0.37 |
| ▸ | CFTR | P13569 | 5/20 | 0.36 |
| ▸ | IKBKB | O14920 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26852629 | 0.80 | HPGD (0.43) | LIMK1CFTRIKBKBLMNAMBOAT4 | |
| SCHEMBL30516416 | 0.77 | LMNA (0.41) | IKBKBLMNA | |
| SCHEMBL565623 | 0.75 | POLB (0.46) | JUNNFKB1NFKB2RELALIMK1 | |
| SCHEMBL13076777 | 0.74 | PIK3CD (0.41) | — | |
| SCHEMBL31028563 | 0.74 | PIK3CD (0.41) | — | |
| SCHEMBL18109672 | 0.74 | POLB (0.44) | LIMK1IKBKBLMNA | |
| SCHEMBL30609423 | 0.74 | LMNA (0.38) | LIMK1IKBKBLMNA | |
| SCHEMBL24558660 | 0.71 | LMNA (0.36) | IKBKBLMNAJAK2 | |
| SCHEMBL30397207 | 0.71 | ALDH1A1 (0.39) | CFTRIKBKBLMNASCN9ACASP1 | |
| SCHEMBL29028859 | 0.71 | ALDH1A1 (0.39) | CFTRIKBKBLMNASCN9ACASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| EP-4522608-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2025-03-19 | — | — | EP | disclosed |
| CN-119546602-A | Pyrrolidone derivatives as inhibitors of nfkb-induced kinase | 詹森药业有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2023217906-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | JUN 713/4885NFKB1 4/4885NFKB2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.